Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
Blood Cancer Journal
|
March 27, 2025
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka, et al.
Current Medical Research and Opinion
|
January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Catherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
NEJM Evidence
|
February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers
Michael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
Blood
|
March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma
Jennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
Blood
|
April 8, 2025
Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
Blood
|
October 29, 2025
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3
Tom van Meerten, Marie José Kersten, Gloria Iacoboni, et al.
Blood
|
October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia
Jennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.
Blood
|
January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.
Blood Advances
|
August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study
Nirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
Blood Cancer Journal
|
March 27, 2025
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka, et al.
Current Medical Research and Opinion
|
January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Catherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
NEJM Evidence
|
February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers
Michael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
Blood
|
March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma
Jennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
Blood
|
April 8, 2025
Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
Blood
|
October 29, 2025
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3
Tom van Meerten, Marie José Kersten, Gloria Iacoboni, et al.
Blood
|
October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia
Jennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.
Blood
|
January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.
Blood Advances
|
August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study
Nirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
Page
of 7